**TITLE:**

Upper Extremity Transplantation in Non-Human Primates: An Orthotopic Model for Translational Research.

**AUTHORS:**

Leonard, David A1,2,3,,

1 Transplantation Biology Research Center,

Massachusetts General Hospital,

Harvard Medical School,

Boston, USA

2 Division of Plastic and Reconstructive Surgery,

Massachusetts General Hospital,

Harvard Medical School,

Boston, USA

3 Department of Plastic & Reconstructive Surgery Research,

University of Manchester,

Manchester, UK

Powell, Harrison1,

1 Transplantation Biology Research Center,

Massachusetts General Hospital,

Harvard Medical School,

Boston, USA

Albritton, Alexander1,

1 Transplantation Biology Research Center,

Massachusetts General Hospital,

Harvard Medical School,

Boston, USA

Shanmugarajah, Kumaran1,2,

1 Transplantation Biology Research Center,

Massachusetts General Hospital,

Harvard Medical School,

Boston, USA

2 Division of Plastic and Reconstructive Surgery,

Massachusetts General Hospital,

Harvard Medical School,

Boston, USA

Mastroianni, Melissa1,2,

1 Transplantation Biology Research Center,

Massachusetts General Hospital,

Harvard Medical School,

Boston, USA

2 Division of Plastic and Reconstructive Surgery,

Massachusetts General Hospital,

Harvard Medical School,

Boston, USA

Lofgren, Sarah1,

1 Transplantation Biology Research Center,

Massachusetts General Hospital,

Harvard Medical School,

Boston, USA

Winter, James1,

1 Transplantation Biology Research Center,

Massachusetts General Hospital,

Harvard Medical School,

Boston, USA

Kurtz, Josef M1,4,

1 Transplantation Biology Research Center,

Massachusetts General Hospital,

Harvard Medical School,

Boston, USA

4 Department of Biology,

Emmanuel College,

Boston, USA

Cetrulo, Curtis L Jr1,2

1 Transplantation Biology Research Center,

Massachusetts General Hospital,

Harvard Medical School,

Boston, USA

2 Division of Plastic and Reconstructive Surgery,

Massachusetts General Hospital,

Harvard Medical School,

Boston, USA

**CORRESPONDING AUTHOR:**

Curtis L. Cetrulo,

Clinical Director Reconstructive Transplantation Program,

Division of Plastic and Reconstructive Surgery,

15 Parkman Street,

Boston, MA, 02114.

Tel: 617-643-7294.

Email address: ccetrulo@mgh.harvard.edu

**KEYWORDS:**

Vascularized composite allotransplantation, reconstructive transplantation, upper extremity transplantation, orthotopic model, non-human primate, translational research

**SHORT ABSTRACT:**

Vascularized composite allotransplantation (VCA) offers unparalleled restoration of function and form following devastating musculoskeletal and soft tissue injury. Surgical techniques have developed rapidly, but immunological and functional outcomes require further study. We described a rigorous non-human primate model of orthotopic upper extremity transplantation for pre-clinical studies immediately preceding clinical translation.

**LONG ABSTRACT:**

Vascularized composite allotransplantation (VCA) is established as a treatment option in the management of complex musculoskeletal and soft tissue trauma and tissue loss. The utility of these procedures is particularly well illustrated by transplantation of specialized anatomical parts such as the upper extremity or craniofacial structures. However, despite encouraging early to medium term outcomes, the potential adverse effects of life-long immunosuppression, necessary to suppress graft rejection, remain a significant cause for concern. Furthermore, the impact and functional significance of chronic rejection in VCA has yet to become clear. Therefore, while the surgical techniques necessary for VCA have developed rapidly, based on decades of experience in autologous free tissue transfer, the immunological aspects of these procedures and the potential functional significance of immunological processes on vascularized composite allografts remain areas in which further research is required to maximize clinical utilization and optimize the risk-benefit balance for patients.

The functional complexity of these procedures, combined with the preclinical nature of many of the research questions, necessitates the use of large animal models to most effectively address some of the outstanding hypotheses. Cynomolgus macaques have become established as one of the premier large animal models for immunological research. This manuscript describes an orthotopic model of upper extremity transplantation in cynomolgus macaques, for translational research in transplant immunology and suitable for detailed study of the impact of immunologic processes on functional outcomes following VCA. The main focus of our laboratory is establishment of transplant tolerance, the specific absence of a destructive immune response against a vascularized composite allograft, in the absence of immunosuppression, and this model represents the most rigorous test of protocols under consideration for translation to the clinic.

**INTRODUCTION:**

Vascularized composite allotransplantation (VCA) is established as a treatment option in the management of complex musculoskeletal and soft tissue trauma and tissue loss. The utility of these procedures is particularly well illustrated by transplantation of specialized anatomical parts such as the upper extremity or those of the craniofacial region, where satisfactory replacement of like with like, consistent with Gillies’ dictum1, using autologous tissue is extremely challenging and results often remain suboptimal.

Surgical development in VCA has been rapid, based on decades of experience in autologous free tissue transfer and microsurgery, and short to medium term results have been encouraging. Functional outcomes have been remarkable, particularly in the context of innervation, with hand transplant recipients appearing to benefit from a positive effect of calcineurin inhibition on peripheral nerve regeneration2. Recipients of both upper extremity and face transplants have reported significant improvements in independence and quality of life post-transplant. VCA also maintains a 1-year graft survival rate close to 100%, far in excess of other branches of transplantation3. However this is offset by a high incidence of acute rejection episodes (up to 90% experience at least one episode within the first year) which most frequently target the skin3,4. Aside from the immediate clinical burden of such episodes, necessitating that patients undergo biopsy and additional therapy, typically with corticosteroid bolus, evidence from a VCA study in rodents links repeated acute rejection episodes with later development of chronic rejection5. Clinically, chronic rejection has not yet been well characterized in VCA, but considering the impact of chronic rejection processes, chiefly chronic allograft vasculopathy, on long term outcomes following solid organ transplantation it remains a cause for concern. Taken together with the side effect profile of conventional immunosuppression regimens, the necessity for further research into the immunologic responses to vascularized composite allografts, and development of novel clinical protocols with reduced risk, improved efficacy, or both is clear. In this context, the overarching goal of our laboratory is the development of clinically applicable protocols for VCA tolerance.

Murine models have been used extensively to gain important insights into the basic mechanisms of immune system function and the establishment and maintenance of immune tolerance6. More recently, advances in microsurgical techniques have facilitated the introduction of murine VCA models, allowing specific study of skin and musculoskeletal tissues in the context of vascularized composites7. However, historically, the vast majority of protocols which successfully achieve tolerance of a transplanted organ or tissue in small animal models fail to translate to large animals or to humans8. In contrast, mixed chimerism-based tolerance protocols originating from murine studies, and validated in non-human primate models9 have been successfully introduced to clinical trials in kidney transplantation10,11. Therefore, in addition to small animal studies, and porcine VCA models which we utilize extensively as a cost-effective large animal model uniquely well suited to the study of cutaneous immunobiology, we believe that rigorous non-human primate models are an important part of the translational research pathway in VCA.

Previous studies, performed prior to the introduction of clinical upper extremity transplantation, sought to investigate the technical feasibility of hand transplantation in baboons12 and of partial hand transplants (composites of the first ray and radial forearm flap) in rhesus macaques13. More recently, the radial forearm flap has been described as a model for study of VCA in cynomolgus macaques14, although this model lacked any functional component. Similarly, Barth and colleagues have described a model of heterotopic transplantation of partial facial allografts15 which they have utilized in a number of studies of novel immunosuppressive regimens and the role of donor bone marrow in this context16,17.

This manuscript describes the methodology used for orthotopic upper extremity transplantation in cynomolgus macaques. This model permits detailed study of the immune status of recipients using the wide variety of validated immunologic techniques and reagents available for this species, including many cross-reactive human reagents. In addition the orthotopic transplantation of an upper extremity, with careful coaptation of nerves and tendons in a manner comparable to hand transplants in the clinical setting, offers the possibility of functional studies, including analysis of peripheral nerve testing and functional neuroimaging studies, which would not be possible in other model systems.

In this model, recipient amputation and procurement of the donor hand, at the level of the distal third of the forearm, proceed in parallel to the point of recipient amputation. The donor hand remains perfused on radial artery and cephalic vein, and the donor is systemically heparinized prior to ligation of the pedicle and radial and ulnar osteotomies. The donor hand is placed on ice, and flushed with heparin-saline and perfusion solution prior to transplantation which proceeds with osteosynthesis, tenorrhaphy of the wrist extensors and flexors for stability, followed by reperfusion via the radial artery, with drainage via anastomosis of the cephalic vein. Additional arterial or venous anastomoses maybe performed if required to achieve optimal circulation. Following reperfusion, transplantation is completed with tenorrhaphy of the digital flexor and extensor tendons, median and ulnar neurorrhaphies, and closure of the skin flaps. The limb is protected in a lightweight fiberglass cast postoperatively. Following intraoperative induction of immunosuppression via the intravenous route, maintenance immunosuppression may be provided intramuscularly or orally, disguised in food. This protocol may be modified to perform autologous replantation as an experimental control.

Typically we observe satisfactory perfusion of the transplanted hand following anastomosis of radial artery and cephalic vein alone. In two cases we have performed secondary arterial anastomoses using branches of the radial artery, which interestingly, appears bifid in these animals. Venous drainage via the cephalic vein has been sufficient in all cases, with the exception of one case in which kinking and occlusion of the vein resulted in thrombosis, congestion and no-reflow phenomenon. Maintenance immunosuppression with tacrolimus, mycophenolate mofetil and methylprednisolone has been sufficient to prevent graft loss to rejection post-transplant. Further studies are underway utilizing this model for investigation of clinically applicable tolerance strategies.

**PROTOCOL:**

All animal procedures described and demonstrated in this publication were conducted in accordance with protocols approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee (IACUC), in accordance with the Guide for the Care and Use of Laboratory Animals and under strict veterinary supervision.

**1. Preoperative Planning and Preparation**

1.1 Use cynomolgus macaques, purchased from approved vendors, with body weight greater than 6 kg. Animals should undergo thorough veterinary evaluation and quarantine prior to surgery. Select donor-recipient pairs on basis of size match, ABO blood group, and additional parameters as necessary for the experiment planned, including major histocompatibility complex (MHC) genotyping and expression of donor-specific markers for chimerism analysis.

1.2 In order to minimize ischemic time, procurement of the donor limb and recipient amputation should proceed in parallel. Plan surgery to ensure coordination of the surgical and anesthetic teams.

1.3 Confirm donor and recipient weights with anesthetic team 24 hours prior to transplant, and finalize orders for any non-anesthetic medications, such as induction immunosuppression, to be administered intraoperatively as required by the experimental protocol.

1.4 Check operating room equipment (critical equipment such as operating microscope and pneumatic tourniquet should be tested frequently and undergo routine preventative maintenance) and set up to facilitate work flow.

1.5 Ensure instruments are available and sterilized (autoclaved or gas sterilized) including reciprocating saw, drill, titanium plating set, microsurgical set, microvascular clamps and general dissecting instruments. In addition to donor and recipient operating tables with arm tables, back tables will be required for each animal, and for the sterile orthopedic equipment.

1.6 Withhold solid food for at least 12 hours prior to surgery for both donor and recipient. Water should be allowed ad libitum at all times.

**2. Induction of Anesthesia and Intraoperative Monitoring**

2.1 On the day of surgery administer premedication (Glycopyrolate 0.01 mg/kg) and sedative (Ketamine 20mg/kg) drugs IM.

2.2 Confirm adequate sedation by observation, remove animals from the cage and transfer to the OR. Remove hair from the surgical site (left arm) and additional sites for vascular access (contralateral arm, lower legs, tail) using clippers.

2.3 Place an appropriately size cuffed endotracheal tube and connect to anesthesia and ventilator circuit. Maintain anesthesia with isoflurane 0.5-3% and, for recipient animals, a continuous infusion of Ketamine 1mg/ml at a rate of 5-10ml/hr.

2.4 Position animals on operating table with left arm extended on arm table, and pneumatic tourniquet in place. Place Bear Hugger forced air warmer to maintain body temperature under anesthesia. Lubricate eyes with veterinary eye ointment to prevent dryness under anesthesia.

2.5 Establish peripheral IV access in short saphenous veins and/or contralateral basilic veins. Administer maintenance fluids (0.9% normal saline, 10ml/kg/hr) and medications intraoperatively.

2.6 Place a percutaneous arterial line in the ventral artery of the tail of recipient animals for continual invasive blood pressure monitoring.

2.7 Insert a self-retaining Foley urinary catheter (5 Fr) and connect to urometer to facilitate strict monitoring of fluid balance.

2.8 Establish monitoring of pulse, blood pressure, respiratory rate, pulse oximetry, capnography, EKG and temperature. In addition assess depth of anesthesia by assessment of jaw tone. Monitor and record these parameters throughout the period of anesthesia.

2.9 Administer preoperative analgesics (Buprenorphine 0.01 mg/kg IV, Banamine 1mg/kg IM) and prophylactic antibiotics (Cefazolin 25mg/kg IM).

2.10 Perform disinfectant skin preparation with solutions of chlorhexidine, povidone-iodine and alcohol and drape the surgical field.

**3. Recipient Preparation**

Induction immunosuppression may be administered intravenously to the recipient during the transplant procedure, however the details of immunosuppressive protocols are expected to be the focus of experimental studies using this model, and to therefore varying considerably. For this reason we have not included specific steps describing the administration of immunosuppressive reagents in this protocol.

3.1 Mark course of cephalic vein and other substantial cutaneous veins with surgical ink. Design and mark skin flaps to interdigitate with donor skin flaps approximately 4cm proximal to radiocarpal joint.

3.2 Elevate and compress arm to exsanguinate, inflate tourniquet to 200 mmHg.

3.3 Incise skin and elevate skin flaps, taking care to preserve cephalic and other cutaneous veins. Ensure hemostasis with bipolar diathermy.

3.4 Open investing fascia and dissect out radial artery and venae commitantes (VCs). Note that the radial artery may be bifid at this level in cynomolgus macaques with each branch accompanied by VCs.

3.5 Protecting cephalic vein and radial vascular bundle, divide the superficial digital flexors. Note that the musculotendinous junction extends further distally in comparison to human anatomy and division of muscle is likely at this level.

3.6 Identify, isolate and divide the median nerve. Section as far distal as possible and mark for later identification.

3.7 Isolate and protect the ulnar nerve and ulnar artery deep to flexor carpi ulnaris, which should be divided. Ligate the ulnar artery with clips and divide; this should be handled carefully as it may be required for secondary arterial anastomosis later. Divide ulnar nerve distally and mark for identification.

3.8 Divide the flexor digitorum profundi and the wrist flexors.

3.9 Divide the digital and wrist extensors.

3.10 Divide pronator quadratus and perform minimal periosteal stripping to prepare the osteotomy sites, which should be measured at 4cm from the radiocarpal joint.

3.11 Ligate and divide radial artery and cephalic vein. Amputate hand with reciprocating saw, taking care to perform well aligned, transverse osteotomies of radius and ulna.

3.12 Deflate tourniquet, ensure hemostasis with bipolar diathermy, ligature-clips and bone wax as necessary. Wrap stump in saline-soaked gauze and monitor recipient condition while awaiting donor hand.

*[Place Figure 1 here]*

**4. Donor Operation – Allograft Procurement**

Procurement of the donor hand proceeds in a similar manner to recipient amputation, with the exception that neurovascular structures sectioned distally in the recipient should be dissected proximally in the donor prior to division, to ensure sufficient length is available for tension-free anastomoses.

4.1 Mark course of cephalic vein and other substantial cutaneous veins with surgical ink. Design and mark skin flaps to interdigitate with donor skin flaps approximately 4cm proximal to radiocarpal joint (Figure 1 A).

4.2 Elevate and compress arm to exsanguinate, and inflate tourniquet to 200 mmHg.

4.3 Incise skin and elevate skin flaps, taking care to preserve cephalic and other cutaneous veins. Ensure hemostasis with bipolar diathermy.

4.4 Open investing fascia and dissect out radial artery and venae commitantes (Figure 1 B).

4.5 Protecting cephalic vein and radial vascular bundle, divide the superficial digital flexors.

4.6 Identify, isolate and dissection out the median nerve, dividing it 1-2cm proximal to the level of the skin incision.

4.7 Divide flexor carpi ulnaris, taking care to protect ulnar nerve and artery lying along its deep margin. Divide ulnar artery and nerve proximally, and mark for identification.

4.8 Divide the flexor digitorum profundi and the wrist flexors.

4.9 Divide the digital and wrist extensors.

4.10 Divide pronator quadratus and perform minimal periosteal stripping to prepare the osteotomy sites, which should be measured at 4cm from the radiocarpal joint.

4.11 Deflate tourniquet, allowing hand to reperfuse via radial artery and cephalic vein (Figure 2 A). Ensure hemostasis. Administer heparin 200 U/kg intravenously.

4.12 Allow hand to perfuse for 20-30 minutes, during which time a tray of sterile ice should be crushed and heparin-saline (100 U/ml) and perfusion solution prepared.

4.13 Ligate and divide radial artery and cephalic vein. The start of ischemic time should be noted.

4.14 Perform radial and ulnar osteotomies with reciprocating saw and remove hand to back table on ice (Figure 2 B).

4.15 Humanely euthanize the donor animal and collect additional tissues as necessitated by your experimental plan.

Note 1: Two options are available for humane euthanasia; an intravenous overdose (200mg/kg) of sodium pentobarbital (Fatal Plus) administered under sedation, or exsanguination under deep anesthesia. Use the later only in experimental circumstances where vital bone marrow or other tissues to which sodium pentobarbital may be toxic must be collected.

Note 2: We routinely collect whole blood volume for isolation of leukocytes for in vitro assays and preparation of packed red cells for transfusion support of anemic animals, bone marrow for transplantation and induction of mixed chimerism, and split thickness skin grafts for later testing of tolerance.

*[Place Figure 2 here]*

**5. Transplantation**

5.1 With the hand on ice, cannulate the radial artery using an anterior chamber needle and 10ml syringe and flush with heparin-saline 100U/ml followed by perfusion solution (University of Wisconsin, or Euro-Collins) until venous effluent is clear.

5.2 Transfer hand to recipient table and ensure donor and recipient osteotomies are parallel and will permit well aligned rigid fixation.

5.3 Perform osteosynthesis with appropriately sized, titanium limited contact dynamic compression plates (LCDCP) and titanium screws. Use 2.0 mm plates for animals between 6 – 10kg. Fix ulna first with a 4-hole plate, followed by radius with a 6-hole plate, 8mm and 10mm screws respectively are appropriate in the majority of cases. Follow AO principles and ensure rigid fixation to minimize risk of nonunion (Figure 3).

5.4 Repair wrist flexors and extensors to stabilize wrist in a neutral position using 3/0 prolene or ethibond suture.

5.5 Repair deep digital flexor tendons to mimic natural digital cascade using 3/0 prolene or ethibond suture.

5.6 Bring in operating microscope and perform microvascular anastomoses of radial artery followed by cephalic vein. The artery can be expected to have a diameter of <1mm and the vein 1-1.5mm, 10/0 nylon suture is appropriate (Figure 4).

5.7 Remove microvascular clamps and allow hand to reperfuse. Note end of ischemic time. Apply lidocaine 1% to vessels to relieve vasospasm, ensure recipient is well hydrated with adequate blood pressure and body temperature, and apply warm saline soaked gauze wraps to the hand. Allow hand to reperfuse for 20-30 minutes during which time the surgical team may rotate or take a short rest.

5.8 Assess perfusion. If adequate (hand warm, bright red bleeding from fingertip following needle prick) proceed with subsequent steps. If inadequate examine anastomoses under microscope for patency, ensure vessel lengths are appropriate to exclude both excess tension and kinking, and if necessary perform additional anastomoses to enhance perfusion. A secondary branch of the radial artery, or the ulnar artery are available, additional dorsal veins may be identified. The venae commitantes of the arteries are of insufficient caliber for reliable anastomosis.

5.9 Perform median and ulnar neurrorhaphies, aiming to do so as far distal as possible, using 8/0 or 9/0 nylon suture.

5.10 Repair superficial digital flexor tendons with 3/0 prolene or ethibond using low-profile side-to-side technique18.

5.11 Perform extensor tenorrhaphies using 3/0 prolene or ethibond, setting tension to allow full range of motion and maintaining digital cascade.

5.12 Interdigitate and close skin flaps using 3/0 nylon simple interrupted sutures, taking care to avoid damage to the cephalic vein or arterial anastomoses (Figure 5 A, B).

5.13 Check perfusion adequate (Figure 5 C) before applying dressings and cast and recovering the animal to its cage.

Note that this protocol may be adapted to perform amputation and autologous replantation if required to address specific experimental aims, by following the procedures for donor procurement and transplantation on a single animal. Shortening osteotomies of 5-10mm to radius and ulna may be necessary to relieve tension on neurovascular structures and facilitate anastomoses.

*[Place Figure 3 here]*

*[Place Figure 4 here]*

**6. Postoperative Care**

6.1 Dress hand and wound with gauze and bulky wool, and apply a full-length fiberglass cast to the arm with the wrist slightly extended, and the metacarpophalangeal and interphalangeal joints loosely flexed in a natural cascade position.

Note: The elbow should be slightly flexed to prevent effortless removal of the cast, while simultaneously avoiding vascular constriction at the antecubital fossa.

6.2 Place animal in a cotton jacket. Secure cast to front of jacket to achieve relief from dependent position.

**Note:** Animals must be acclimated to wearing of jackets and casts prior to commencing study.

6.3 Ensure adequate hydration and analgesia. If placed in protective jacket, a fentanyl patch 1-4g/kg/hr may be placed to provide postoperative analgesia. Alternatively buprenorphine 0.01mg/kg IM must be administered twice daily for 72 hours, more frequently if clinical signs of pain are observed.

6.4 Wean from anesthesia, discontinue monitoring.

6.5 Return to cage, which should be warmed with a heat lamp, and monitor continually until fully alert and recovered from anesthesia.

6.6 Perform examination of the transplanted hand daily or twice daily for the first 72 hours postoperatively to ensure adequate perfusion and facilitate rapid intervention if necessary to revise anastomoses etc. Short duration sedation for these procedures may be induced with intramuscular injection of ketamine (1-4 mg/kg) and dexmedetomidine (5-10 g/kg), followed by atipamezole reversal. The frequency of checks can be reduced to twice weekly after the immediate postoperative period.

6.7 Perform two-view radiographs on post-operative day 1 to ensure fixation is appropriate and the position acceptable.

6.8 Administer immunosuppressive medications according to individual experimental protocols. Details of immunosuppressive regimens vary, but conventional immunosuppression may be administered daily via a combination of IM and oral routes. Draw blood twice weekly to monitor drug levels.

*[Place Figure 5 here]*

**REPRESENTATIVE RESULTS:**

Following a series of post-mortem dissections to confirm the anatomy of the cynomolgus monkey forearm and to determine the feasibility of transplantation and revascularization, we have performed a series of two autologous replantations and four allotransplants across full MHC barriers. Total operating time averaged 11-12 hours. Mean ischemic time in both groups was 3 hours. All microvascular anastomoses were performed using conventional suture techniques for both artery and vein, which had diameters of 0.75-1mm and 1-1.5mm respectively. All anastomoses were demonstrably patent with no primary failures.

In the autologous replantation group, one animal unfortunately developed respiratory complications under anesthesia, secondary to endotracheal tube trauma, from which resuscitation could not be achieved. The second animal in this group tolerated the procedure well, made impressive functional recovery, including use of the hand in locomotion, grooming and as an assist hand while feeding and manipulating objects. This animal remains under follow up over 1 year post-operatively.

Outcomes following allotransplantation have highlighted the critical importance of precise microsurgical technique, and highlighted the challenges of microvascular procedures on this small scale. Two animals unfortunately required early euthanasia due to microvascular compromise; in one case excess length following venous anastomosis permitted the development of kinking and venous thrombosis on POD2. Despite emergency revision a no-reflow state had developed and the hand could not be reperfused. In another case, despite patent anastomoses, and treatment with topical lidocaine 1% for relief of vasospasm, perfusion of the hand was poor postoperatively and despite medical optimization, warming, and anticoagulation perfusion remained poor. Persisting ischemia declared over the first postoperative week and the animal was euthanized on POD7.

The remaining two animals in the initial allotransplant group had smooth operative courses, and made excellent post-operative recoveries (Figure 6A, B). The first was followed to an experimental end point 4 months post-transplant, during which period immunosuppression induced with three doses of anti-thymocyte globulin (ATGAM) 50mg/kg and maintained with FK506 0.1mg/kg/day, MMF 300mg/day and methylprednisolone tapered from over the first two weeks from 40mg/day to a maintenance dose of 1mg/day. This regimen resulted in rejection-free survival (Figure 6C), with the exception of 1 episode of acute rejection of skin which followed tapering of MMF to 100mg/day due to a period of inappetence. Signs of rejection resolved rapidly in response to steroid bolus and return to standard MMF dosing. The final animal in this group is currently 3 weeks post-transplant, remains clinically well, and shows no signs of rejection.

*[Place Figure 6 here]*

**Figure Legends:**

**Figure 1: Marking and dissection for procurement of NHP donor hand.**

A) Skin flaps are marked approximately 4cm from wrist on both recipient and donor to ensure skin flaps interdigitate properly following transplantation. Note that the course of the cephalic vein is also marked. B) Dissecting proximally along the radial vascular bundle to procure additional length facilitates tension-free anastomosis.

**Figure 2: Isolation and amputation of the donor hand.**

A) Following dissection and transection of all major structures except the radius, ulna, radial artery and cephalic vein the tourniquet is released, the donor heparinized and the hand reperfused for 20-30 minutes prior to procurement. B) Following ligation and division of the radial artery and cephalic vein osteotomies are performed with a reciprocating saw.

**Figure 3: NHP hand transplantation: Osteosynthesis.**

A) Osteosynthesis of ulna and radius is performed using titanium LC-DCPs according to AO principles. Note microvascular clamps on proximal vessels in preparation for anastomosis. B) AP and C) Lateral radiographs demonstrating close approximation and good alignment of radius and ulna post-transplant.

**Figure 4: NHP hand transplantation: Reperfusion.**

Following anastomoses of radial artery and cephalic vein, visible above plates in this photograph, the hand is reperfused for 20-30 minutes and perfusion assessed prior to continuing with repair of flexor and extensor tendons, median and ulnar nerves and closure of skin flaps.

**Figure 5: Post-transplant appearance:**

A) Radial-oblique and B) ulnar-oblique views immediately following closure of skin flaps. C) Bright red bleeding from fingertip following needle-prick confirms the hand is well perfused prior to application of dressings and protective cast.

**Figure 6: Representative result:**

A) Radial and B) Palmar views demonstrating status 3 months post hand transplantation. Note sutures following protocol biopsy, which confirmed rejection-free status. C) Hand transplant biopsy specimen demonstrating absence of rejection. Immunosuppression was maintained with FK506 0.1mg/kg/day, MMF 300mg/day and Methylprednisolone 1mg/day.

**DISCUSSION:**

Non-human primate models are widely considered the final step on the translational research pathway prior to clinical trial. Positive results in such models are viewed with particular importance in fields, such as VCA, where results of current therapies are acceptable, albeit not always optimal, and where patient survival is expected to be high without intervention – thus establishing that the ethical standard for any new therapy should be beneficence rather than non-maleficence.

Previously described non-human primate models of VCA have achieved transplantation of the necessary tissue types, and have provided insights into the immune response to these tissues under conventional immunosuppression14,15 and some novel protocols16. However, these models include no functional component by which to assess this important aspect of VCA. This orthotopic upper extremity transplantation model, in contrast, is closely analogous to clinical hand transplant procedures, and provides a unique opportunity to study not only the immune response to the transplanted tissues, but to investigate in detail the impact of rejection, or aspects of novel tolerance or immunomodulatory protocols on functional outcome. Representative results from such studies are not yet available, but investigation of peripheral nerve recovery, functional testing, and advanced imaging studies are planned.

This model is technically challenging, and presents a steep learning curve as illustrated by the representative results presented. High quality, rigid boney fixation is critical in avoiding non-union. Precise microvascular technique is also imperative, as we have found this model highly sensitive to even minor excess vessel length, particularly following venous anastomosis. It is also resource intensive, requiring an appropriate non-human primate research facility, expert veterinary anesthetic support and a team of experienced reconstructive microsurgeons. Clearly structured rehabilitation to maximize functional outcomes is not possible in NHPs as it is in patients, and this could represent a limitation of this model when it comes to future functional studies. However we have been impressed by the considerable degree of function which animals recovery spontaneously, including use of the hand in grooming, as an assist hand in feeding, and for locomotion. We believe this model represents a valuable tool in the effort to develop and validate novel protocols to improve the immunologic management of VCA, and we hope, ultimately to facilitate the introduction of a safe and effective protocol for induction of VCA tolerance to clinical trial.

**ACKNOWLEDGMENTS:**

The authors wish to acknowledge funding from the Massachusetts General Hospital Division of Plastic and Reconstructive Surgery and the US Department of Defense Reconstructive Transplantation Research Consortium (W81XWH-13-2-0062). David Leonard was supported by a Novartis Scientist Scholarship from the American Society of Transplant Surgeons. We wish to thank Betsy Neylon and Elena Shubina for expert operating room support.

**DISCLOSURES:**

The authors have nothing to disclose.

**REFERENCES**

1. Millard, D.R. & Gillies, H.D. *The Principles and Art of Plastic Surgery*. Little & Brown, (1957).

2. Doolabh, V.B. & Mackinnon, S.E. FK506 accelerates functional recovery following nerve grafting in a rat model. *Plast.Reconstr.Surg.* **103** (7), 1928-1936, (1999).

3. Petruzzo, P. *et al.* The International Registry on Hand and Composite Tissue Transplantation. *Transplantation.* **90** (12), 1590-1594, doi:10.1097/TP.0b013e3181ff1472 [doi] (2010).

4. Hautz, T. *et al.* Standardizing skin biopsy sampling to assess rejection in vascularized composite allotransplantation. *Clin Transplant.* **27** (2), E81-E90, doi:10.1111/ctr.12086 [doi] (2013).

5. Unadkat, J.V. *et al.* Composite tissue vasculopathy and degeneration following multiple episodes of acute rejection in reconstructive transplantation. *Am.J Transplant.* **10** (2), 251-261, doi:AJT2941 [pii];10.1111/j.1600-6143.2009.02941.x [doi] (2010).

6. Sykes, M. Mechanisms of tolerance induced via mixed chimerism. *Front Biosci.* **12** 2922-2934, doi:2282 [pii] (2007).

7. Sucher, R. *et al.* Mouse hind limb transplantation: a new composite tissue allotransplantation model using nonsuture supermicrosurgery. *Transplantation.* **90** (12), 1374-1380, doi:10.1097/TP.0b013e3181ff4fc3 [doi] (2010).

8. Sachs, D.H. Tolerance: of mice and men. *J Clin Invest.* **111** (12), 1819-1821, (2003).

9. Kawai, T. *et al.* Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. *Transplantation.* **59** (2), 256-262, (1995).

10. Kawai, T. *et al.* HLA-mismatched renal transplantation without maintenance immunosuppression. *N Engl J Med.* **358** (4), 353-361, (2008).

11. Kawai, T., Sachs, D.H., Sykes, M., & Cosimi, A.B. HLA-mismatched renal transplantation without maintenance immunosuppression. *N.Engl.J Med.* **368** (19), 1850-1852, doi:10.1056/NEJMc1213779 [doi] (2013).

12. Daniel, R.K. *et al.* Tissue transplants in primates for upper extremity reconstruction: a preliminary report. *J Hand Surg.Am.* **11** (1), 1-8, (1986).

13. Hovius, S.E. *et al.* Replantation of the radial side of the hand in the rhesus monkey: anatomical and functional aspects. A preliminary study to composite tissue allografting. *J Hand Surg.Br.* **17** (6), 651-656, (1992).

14. Cendales, L.C. *et al.* Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. *Transplantation.* **80** (10), 1447-1454, doi:00007890-200511270-00016 [pii] (2005).

15. Barth, R.N. *et al.* Facial subunit composite tissue allografts in nonhuman primates: I. Technical and immunosuppressive requirements for prolonged graft survival. *Plast.Reconstr.Surg.* **123** (2), 493-501, doi:10.1097/PRS.0b013e3181954edd [doi];00006534-200902000-00008 [pii] (2009).

16. Barth, R.N. *et al.* Vascularized bone marrow-based immunosuppression inhibits rejection of vascularized composite allografts in nonhuman primates. *Am.J Transplant.* **11** (7), 1407-1416, doi:10.1111/j.1600-6143.2011.03551.x [doi] (2011).

17. Barth, R.N. *et al.* Prolonged survival of composite facial allografts in non-human primates associated with posttransplant lymphoproliferative disorder. *Transplantation.* **88** (11), 1242-1250, doi:10.1097/TP.0b013e3181c1b6d0 [doi];00007890-200912150-00004 [pii] (2009).

18. Brown, S.H. *et al.* Mechanical strength of the side-to-side versus Pulvertaft weave tendon repair. *J Hand Surg.Am.* **35** (4), 540-545, doi:S0363-5023(10)00050-X [pii];10.1016/j.jhsa.2010.01.009 [doi] (2010).